Drug Trial Radar · NCT02605122
Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia
Last checked: Nov 19, 2026Latest source record: Jan 3, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
97
Actual
Start
Apr 2016
Primary completion
Mar 21, 2018
Study completion Mar 21, 2018
Sponsor
- Lead sponsor
- Melinta Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Biomedical Advanced Research and Development Authority
- First posted
- Nov 16, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 months, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2/3, randomized, open-label, active control, multi-center study to assess the safety and efficacy of solithromycin in children and adolescents with community-acquired bacterial pneumonia (CABP).
Conditions
- Community-acquired Bacterial Pneumonia
Interventions
SolithromycinDrug
Standard of CareDrug
Age- and weight-based dosing as appropriate per sites standard of care.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overview of Adverse Events By Treatment ArmTime frame: Up to 28 days post-treatment
Locations
58 sites in 6 countries. Site status is shown where the registry gives one.
Site not named
Little Rock, Arkansas
Site not named
Los Angeles, California
Site not named
Sacramento, California
Site not named
San Diego, California
Site not named
Washington D.C., District of Columbia
Site not named
Tampa, Florida
Site not named
Louisville, Kentucky
Site not named
Omaha, Nebraska
Site not named
Las Vegas, Nevada
Site not named
Durham, North Carolina
Site not named
Greenville, North Carolina
Site not named
Toledo, Ohio
Site not named
Portland, Oregon
Site not named
Hershey, Pennsylvania
Site not named
Memphis, Tennessee
Site not named
Amarillo, Texas
Site not named
Houston, Texas
Site not named
Splendora, Texas
Site not named
Charlottesville, Virginia
Site not named
Richmond, Virginia
Site not named
Roanoke, Virginia
Site not named
Pleven, Bulgaria
Site not named
Plovdiv, Bulgaria
Site not named
Rousse, Bulgaria
Site not named
Sofia, Bulgaria
Site not named
Sofia, Bulgaria
Site not named
Sofia, Bulgaria
Site not named
Vratsa, Bulgaria
Site not named
Budapest, Hungary
Site not named
Budapest, Hungary
Site not named
Budapest, Hungary
Site not named
Budapest, Hungary
Site not named
Cegléd, Hungary
Site not named
Debrecen, Hungary
Site not named
Győr, Hungary
Site not named
Gyula, Hungary
Site not named
Mosdós, Hungary
Site not named
Nagykanizsa, Hungary
Site not named
Nyíregyháza, Hungary
Site not named
Szeged, Hungary
Showing 40 of 58 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.